Cargando…
Differences in clinical outcomes between HER2-negative and HER2-positive luminal B breast cancer
The clinical features and prognosis of breast cancer can vary widely, depending on the molecular subtype. Luminal B breast cancers are usually either estrogen receptor-positive and/or progesterone receptor-positive with high proliferation of Ki67 index, or HER2 positive (HER2+). The authors compared...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470803/ https://www.ncbi.nlm.nih.gov/pubmed/37653831 http://dx.doi.org/10.1097/MD.0000000000034772 |
_version_ | 1785099763526402048 |
---|---|
author | Kang, Byeongju Lee, Jeeyeon Jung, Jin Hyang Kim, Wan Wook Keum, Heejung Park, Ho Yong |
author_facet | Kang, Byeongju Lee, Jeeyeon Jung, Jin Hyang Kim, Wan Wook Keum, Heejung Park, Ho Yong |
author_sort | Kang, Byeongju |
collection | PubMed |
description | The clinical features and prognosis of breast cancer can vary widely, depending on the molecular subtype. Luminal B breast cancers are usually either estrogen receptor-positive and/or progesterone receptor-positive with high proliferation of Ki67 index, or HER2 positive (HER2+). The authors compared the clinicopathologic factors and survival rates of different subtypes of luminal B breast cancer according to HER2 status. Between 2009 and 2013, 1131 cases of breast cancer were reviewed and characterized as 1 of 4 different molecular subtypes based on their immunohistochemical results: luminal A, luminal B, HER2+, or triple-negative breast cancer. From these, luminal B breast cancers were extracted and the clinical features and prognosis of the HER2- and the HER2 + subtypes were compared. Survival differed significantly based on the molecular subtype regardless of whether or not the patient received treatment with neoadjuvant chemotherapy. While patients with HER2- luminal B breast cancer who received neoadjuvant chemotherapy had better prognoses, patients with HER2 + luminal B breast cancer who did not receive neoadjuvant chemotherapy had better prognoses. Luminal B breast cancers showed different clinical outcomes and survival rates according to HER2 gene overexpression type. Physicians should consider these results when they establish a treatment strategy. |
format | Online Article Text |
id | pubmed-10470803 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-104708032023-09-01 Differences in clinical outcomes between HER2-negative and HER2-positive luminal B breast cancer Kang, Byeongju Lee, Jeeyeon Jung, Jin Hyang Kim, Wan Wook Keum, Heejung Park, Ho Yong Medicine (Baltimore) 5700 The clinical features and prognosis of breast cancer can vary widely, depending on the molecular subtype. Luminal B breast cancers are usually either estrogen receptor-positive and/or progesterone receptor-positive with high proliferation of Ki67 index, or HER2 positive (HER2+). The authors compared the clinicopathologic factors and survival rates of different subtypes of luminal B breast cancer according to HER2 status. Between 2009 and 2013, 1131 cases of breast cancer were reviewed and characterized as 1 of 4 different molecular subtypes based on their immunohistochemical results: luminal A, luminal B, HER2+, or triple-negative breast cancer. From these, luminal B breast cancers were extracted and the clinical features and prognosis of the HER2- and the HER2 + subtypes were compared. Survival differed significantly based on the molecular subtype regardless of whether or not the patient received treatment with neoadjuvant chemotherapy. While patients with HER2- luminal B breast cancer who received neoadjuvant chemotherapy had better prognoses, patients with HER2 + luminal B breast cancer who did not receive neoadjuvant chemotherapy had better prognoses. Luminal B breast cancers showed different clinical outcomes and survival rates according to HER2 gene overexpression type. Physicians should consider these results when they establish a treatment strategy. Lippincott Williams & Wilkins 2023-08-25 /pmc/articles/PMC10470803/ /pubmed/37653831 http://dx.doi.org/10.1097/MD.0000000000034772 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | 5700 Kang, Byeongju Lee, Jeeyeon Jung, Jin Hyang Kim, Wan Wook Keum, Heejung Park, Ho Yong Differences in clinical outcomes between HER2-negative and HER2-positive luminal B breast cancer |
title | Differences in clinical outcomes between HER2-negative and HER2-positive luminal B breast cancer |
title_full | Differences in clinical outcomes between HER2-negative and HER2-positive luminal B breast cancer |
title_fullStr | Differences in clinical outcomes between HER2-negative and HER2-positive luminal B breast cancer |
title_full_unstemmed | Differences in clinical outcomes between HER2-negative and HER2-positive luminal B breast cancer |
title_short | Differences in clinical outcomes between HER2-negative and HER2-positive luminal B breast cancer |
title_sort | differences in clinical outcomes between her2-negative and her2-positive luminal b breast cancer |
topic | 5700 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470803/ https://www.ncbi.nlm.nih.gov/pubmed/37653831 http://dx.doi.org/10.1097/MD.0000000000034772 |
work_keys_str_mv | AT kangbyeongju differencesinclinicaloutcomesbetweenher2negativeandher2positiveluminalbbreastcancer AT leejeeyeon differencesinclinicaloutcomesbetweenher2negativeandher2positiveluminalbbreastcancer AT jungjinhyang differencesinclinicaloutcomesbetweenher2negativeandher2positiveluminalbbreastcancer AT kimwanwook differencesinclinicaloutcomesbetweenher2negativeandher2positiveluminalbbreastcancer AT keumheejung differencesinclinicaloutcomesbetweenher2negativeandher2positiveluminalbbreastcancer AT parkhoyong differencesinclinicaloutcomesbetweenher2negativeandher2positiveluminalbbreastcancer |